Cite
MLA Citation
Shun Lu et al.. “Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.” Lancet oncology, vol. 23, no. 9, 2022, pp. 1167–1179. http://access.bl.uk/ark:/81055/vdc_100164418937.0x000014